Health and population

Health and population dynamics are intertwined, embodying an intricate relationship with significant implications on the Sustainable Development Goals (SDGs). Health is fundamentally at the center of these 17 global goals, aimed to transform the world by 2030. Specifically, Goal 3 endeavors to "Ensure healthy lives and promote well-being for all at all ages." It acknowledges that health is pivotal to human life quality, social cohesion, and sustainable development. Inextricably linked to this are the complexities of population dynamics, including growth rates, age structure, fertility and mortality rates, and migration patterns.

With the world's population projected to exceed 9.7 billion by 2050, the pressure on health systems will undoubtedly escalate. The demographic transition, with an aging population and an increasing prevalence of non-communicable diseases, poses new challenges for health systems globally. Additionally, areas with high fertility rates often overlap with extreme poverty, resulting in heightened health risks, including higher maternal and child mortality rates, malnutrition, and infectious diseases.

Moreover, rapid urbanization and migration present both opportunities and threats to health. While urban areas may provide better access to healthcare, they also harbor risks of disease transmission, air and water pollution, and social determinants of health like inadequate housing and social inequality. Simultaneously, migrants often face disproportionate health risks due to unstable living conditions, exploitation, and limited access to healthcare services.

Achieving the SDGs will necessitate comprehensive approaches that consider the intricate interplay of health and population dynamics. It means strengthening health systems, promoting universal health coverage, and addressing social determinants of health. It also implies crafting policies that recognize demographic realities and foster an environment conducive to sustainable development. Only by understanding and harnessing these dynamics can the world meaningfully progress towards realizing the SDGs, ensuring healthy lives and well-being for all.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 10: Reduced Inequalities by presenting ASD as a complex, multisystem neurodevelopmental condition with origins in prenatal life.
This content aligns with Goal 3: Good Health and Wellbeing and Goal 10: Reduced Inequalities by reviewing the current therapies for neurological disorders and their limitations.
Elsevier,

The Youth Athlete: A Practitioner's Guide to Providing Comprehensive Sports Medicine Care, Volume , 1 January 2023

This content aligns with Goal 3: Good Health and Wellbeing and Goal 10: Reduced Inequalities by treating access and inclusion as human rights issue and highlighting information to providers about caring for athletes with physical disabilities.
Elsevier,

Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging, Volume , 1 January 2023

This content aligns with Goal 3: Good Health and Wellbeing and Goal 10: Reduced Inequalities by discussing the application of cognitive behavior therapy, an evidence-based psychological approach in adolescents suffering from Asperger syndrome with comorbid depressive disorder.
This content aligns with Goal 3: Good Health and Wellbeing and Goal 10: Reduced inequalities by exploring the disability-adjusted life years (DALYs) caused by neurological disorders and the effect of that burden on society.
Screenshot of Educational Video
This article ties to SDG 3. This resource, created together by Osmosis and the National Organization for Rare Diseases (NORD), aims to increase the knowledge and awareness about the rare disease Achondroplasia, the most commonly occurring form of skeletal dysplasia that occurs in approximately 1 in 20,000-30,000 live births.
This content supports the SDG Goal 3: Good health and well-being by formulating an epidemiological mathematical model that demonstrates the transmission of the hepatitis B virus for use in research.
Elsevier,

Overcoming Obstacles in Drug Discovery and Development
Surmounting the Insurmountable—Case Studies for Critical Thinking
2023, Pages 215-222

This content aligns with Goal 3: Good Health and Wellbeing by identifying the reactive metabolite responsible for the species-specific nephrotoxicity observed in rats dosed with efavirenz provide a framework for addressing nonclinical toxicities and clinical risk and providing a solid scientific basis for regulatory review.
This review supports SDG3 by detailing the current fundamental knowledge of HDV lifecycle and review antiviral treatments under development against this virus, outlining their respective mechanisms-of-action. Finally, it describes the antiviral effect these compounds are showing in ongoing clinical trials, discussing their promise and potential pitfalls for managing HDV infected patients.
This article supports SDG 3 as chronic hepatitis B (HBV) and C virus (HCV) infections represent significant public health issues internationally. This paper aims to evaluate the efficacy of hepatitis B vaccination in HCV-related chronic liver disease and identify possible factors that may contribute to hypo-responsiveness in those patients.

Pages